La Jolla Pharmaceutical Company : LifeSci Capital Initiates Coverage of La Jolla Pharmaceutical Company

Developing a Novel Vasopressor for Clinically-Refractory Hypotension (CRH)

Report Available here: www.lifescicapital.com/equity-research/lajolla/

NEW YORK, NY / ACCESSWIRE / January 23, 2017 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of La Jolla Pharmaceutical Company (NasdaqCM: LJPC), a company focused on the development of innovative therapies for life-threatening conditions. La Jolla's lead candidate is LJPC-501, a proprietary, synthetic formulation of the human peptide angiotensin II, that is being developed as a novel vasopressor treatment for distributive shock, whereby insufficient blood flow to maintain proper organ perfusion leads to organ damage and death.

Distributive shock is first treated with fluid resuscitation and then catecholamines like norepinephrine. However, as many as 40% of patients do not achieve an adequate mean arterial blood pressure (MAP) with well-tolerated doses of catecholamines. For these patients, either increasing the initial catecholamine dose or adding on a second vasopressor (catecholamine or vasopressin) exposes the patient to toxicity risks and a heightened mortality risk exceeding 80%. These patients are considered to have clinically-refractory or catecholamine-resistant hypotension (CRH).

LJPC-501 is a complementary treatment for CRH patients that raises MAP through an alternate biological pathway relative to catecholamines and vasopressin. Thus, for some patients refractory to existing treatments, LJPC-501 may offer a third vasopressor pathway to activate in order to increase MAP. In addition, depending on the safety and efficacy data generated in the ongoing ATHOS 3 Phase 3 trial, LJPC-501 may provide comparable efficacy in raising MAP to existing third-line options with a better tolerability profile. The data from the trial will play an important role in shaping where LJPC-501 fits into the current treatment paradigm for distributive shock.

In a 38 page Initiation Report, LifeSci Capital explains the Company's development strategy, landscape of existing therapies, and expected commercial strategy for LJPC-501 if it is approved.

Dr. Sherman's full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on La Jolla Pharmaceutical Company as developments occur.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients' businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company's website, www.lifescicapital.com.

Analyst Contact:

SOURCE: LifeSci Capital, LLC